CD200 and cancer: Although research is limited on using CD200 as a therapeutic, some laboratories have focused on using CD200 blocking antibodies to prolong the survival of renal and cardiac allografts [145], decrease inflammation associated with arthritis [146], various autoimmune diseases [147], and a subset of cancers involving upregulated CD200 [148].